← Leaderboards
Fukun Guo
Cincinnati Childrens Hosp Med Ctr
$3,563,530
Attributed
$5,264,329
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $594.4K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,264,329 · 5
By mechanism
R01$4,493,599 · 3
R56$397,500 · 1
R21$373,230 · 1
Top collaborators
- Yi Zheng7 shared
Most similar at Cincinnati Childrens Hosp Med Ctr
Same institution · by research overlap
- Susanne Irmtraud Wells$12,656,530
- Paul R Andreassen$3,175,027
- Masato Nakafuku$2,334,338
- Paul W. Spearman$26,612,118
- Kenneth J Campbell$13,429,793
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularSignal TransductionMediatingCellsPathway InteractionsT-LymphocyteIn VivoCell LineImmuneMalignant NeoplasmsTumorIn VitroSignal PathwayDefectPublic Health RelevanceCell PhysiologyClinicLengthNuclearInflammatoryImmunotherapyImpairmentMouse ModelGuanosine Triphosphate Phosphohydrolases
Grant awards (14)
Rational targeting of Cdc42 to benefit immunotherapy$594,402
R01 · FY2025 · CA
Rational targeting of Cdc42 to benefit immunotherapy$594,402
R01 · FY2024 · CA
The role of transcription elongation defects in immunotherapy resistance in cancers$437,206
R01 · FY2023 · CA · contact PI
The role of transcription elongation defects in immunotherapy resistance in cancers$437,202
R01 · FY2022 · CA · contact PI
The role of transcription elongation defects in immunotherapy resistance in cancers$446,129
R01 · FY2021 · CA · contact PI
The role of transcription elongation defects in immunotherapy resistance in cancers$446,129
R01 · FY2020 · CA · contact PI
The role of transcription elongation defects in immunotherapy resistance in cancers$446,129
R01 · FY2019 · CA · contact PI
RhoA in T Cell-mediated Airway Inflammation$397,500
R56 · FY2018 · HL · contact PI
Novel Signaling Function of Cdc42 GTPase in vivo$273,000
R01 · FY2017 · GM · contact PI
Novel Signaling Function of Cdc42 GTPase in vivo$273,000
R01 · FY2016 · GM · contact PI
Novel therapeutics of targeting mTOR pathway in T-cell leukemia$203,580
R21 · FY2016 · CA · contact PI
Novel Signaling Function of Cdc42 GTPase in vivo$273,000
R01 · FY2015 · GM · contact PI
Novel therapeutics of targeting mTOR pathway in T-cell leukemia$169,650
R21 · FY2015 · CA · contact PI
Novel Signaling Function of Cdc42 GTPase in vivo$273,000
R01 · FY2014 · GM · contact PI